The Potential of Neuraminidase as an Antigen for Nasal Vaccines To Increase Cross-Protection against Influenza Viruses.

导出 OA

翻译打印收藏纠错

第一作者： Atsushi,Kawai

第一单位： Laboratory of Nano-design for Innovative Drug Development, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan.

作者： Atsushi,Kawai ^[1] ; Yasuyuki,Yamamoto ^[2] ; Takuto,Nogimori ^[3] ; Kohei,Takeshita ^[4] ; Takuya,Yamamoto ^[5] ; Yasuo,Yoshioka ^[6]

作者单位： Laboratory of Nano-design for Innovative Drug Development, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan. ^[1] Vaccine Creation Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Osaka, Japan. ^[2] Vaccine Creation Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan. ^[3] BIKEN Center for Innovative Vaccine Research and Development, The Research Foundation for Microbial Diseases of Osaka University, Suita, Osaka, Japan. ^[4] Laboratory of Immunosenescence, National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Osaka, Japan. ^[5] RIKEN SPring-8 Center, Sayo, Hyogo, Japan. ^[6] Global Center for Medical Engineering and Informatics, Osaka University, Suita, Osaka, Japan. ^[7]

关键词 IgA adjuvant epitope hemagglutinin influenza virus nasal vaccine neuraminidase upper respiratory tract vaccine